Frazier Life Sciences Management, L.P. Tarsus Pharmaceuticals, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $2.36 Billion
- Q3 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 1,167,527 shares of TARS stock, worth $84.3 Million. This represents 2.93% of its overall portfolio holdings.
Number of Shares
1,167,527
Previous 1,397,527
16.46%
Holding current value
$84.3 Million
Previous $56.6 Million
22.56%
% of portfolio
2.93%
Previous 2.99%
Shares
5 transactions
Others Institutions Holding TARS
# of Institutions
231Shares Held
45MCall Options Held
51.6KPut Options Held
15.8K-
Black Rock Inc. New York, NY3.27MShares$236 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.18MShares$229 Million2.52% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$217 Million5.63% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.67MShares$192 Million5.1% of portfolio
-
Jennison Associates LLC2.6MShares$188 Million0.09% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.92B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...